Calcium channel antagonists suppress cross-tolerance to the anxiogenic effects of d-amphetamine and nicotine in the mouse elevated plus maze test

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 1, 2008, Pages 54-61

  Biala, Grazyna ^a   Kruk, Marta ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Anxiety; Calcium channel antagonists; d amphetamine; Elevated plus maze; Mice; Nicotine

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DEXAMPHETAMINE; DILTIAZEM; FLUNARIZINE; NICOTINE; NIMODIPINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; INJECTION; LONG TERM EXPOSURE; MALE; MAZE TEST; MOUSE; NONHUMAN; PROVOCATION TEST;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; CALCIUM CHANNEL BLOCKERS; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG TOLERANCE; MALE; MAZE LEARNING; MICE; NICOTINE; TIME FACTORS;

EID: 38349053349     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.07.006     Document Type: Article

References (52)

1. Bergink V., van Megen H.J., and Westenberg H.G. Glutamate and anxiety. Eur Neuropsychopharmacol 14 (2004) 175-183
2. Biala G. Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents. Pol J Pharmacol 55 (2003) 327-335
3. Biala G., and Budzynska B. Effects of acute and chronic nicotine on elevated plus maze in mice: involvement of calcium channels. Life Sci 79 (2006) 81-88
4. Biala G., and Weglinska B. Calcium channel antagonists attenuate cross-sensitization to the rewarding and/or locomotor effects of nicotine, morphine and MK-801. J Pharm Pharmacol 56 (2004) 1021-1028
5. Biala G., and Weglinska B. On the mechanism of cross-tolerance between morphine-and nicotine-induced antinociception: involvement of calcium channels. Prog Neuro-Psychopharmacol Biol Psychiat 30 (2006) 15-21
6. Birrell C.E., and Balfour D.J.K. The influence of nicotine pretreatment on mesoaccumbens dopamine overflow and locomotor responses to d-amphetamine. Psychopharmacology 140 (1998) 142-149
7. Brandon T.H. Expectancies for tobacco smoking. In: Kirsh I. (Ed). How expectancies shape experience (1999), American Psychological Association 263-299
8. Broni J.D., O'Neill A.B., Kim D.J., and Decker M.W. Nicotine receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol 238 (1993) 1-8
9. Cancela L.M., Basso A.M., Martijena I.D., Capriles N.R., and Molina V.A. A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study. Brain Res 909 (2001) 179-186
10. Celik E., Uzbay T., and Karakas S. Caffeine and amphetamine produce cross-sensitization to nicotine-induced locomotor activity in mice. Prog Neuro-Psychopharmacol Biol Psychiat 30 (2006) 50-55
11. Collins S.L., and Izenwasser S. Chronic nicotine differentially alters cocaine-induced locomotor activity in adolescent vs. adult male and female rats. Neuropharmacology 46 (2004) 349-362
12. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Onaivi E.S., and Tyers M.B. Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. Pharmacol Biochem Behav 36 (1990) 97-104
13. Damaj M.I. Calcium-acting drugs modulate expression and development of chronic tolerance to nicotine-induced antinociception in mice. J Pharmacol Exp Ther 315 (2005) 959-964
14. Damaj M.I., and Martin B.R. Calcium agonists and antagonists of the dihydropyridine type: effect on nicotine-induced antinociception and hypomotility. Drug Alcohol Depend 32 (1993) 73-79
15. Dani J.A., Ji D., and Zhou F.M. Synaptic plasticity and nicotine addiction. Neuron 31 (2001) 349-352
16. Dawson G.R., Crawford S.P., Collinson N., Iversen S.D., and Trickleback M.D. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology 118 (1995) 316-323
17. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393 (2000) 295-314
18. El Ganouni S., Hanoun N., Boni C., Tazi A., Hakkou F., and Hamon M. Prevention of diazepam withdrawal syndrome by nifedipine - behavioural and neurochemical studies. Pharmacol Biochem Behav 79 (2004) 269-277
19. File S.E., Cheeta S., and Kenny P.J. Neurobiological mechanisms by which nicotine mediates different types of anxiety. Eur J Pharmacol 393 (2000) 231-236
20. Hall W., Hando J., Darke S., and Ross J. Psychological morbility and route of administration among amphetamine users in Australia. Addiction 91 (1996) 81-87
21. Handley S.L. 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther 66 (1995) 103-148
22. Irvine E.E., Cheeta S., and File S.E. Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine. Behav Pharmacol 10 (1999) 691-697
23. Irvine E.E., Cheeta S., and File S.E. Development of tolerance to nicotine's anxiogenic effect in the social interaction test. Brain Res 894 (2001) 95-100
24. Karst H., Nair S., Velzing E., Rumpff-van Essen L., Slagter E., Shinnick-Gallagher P., and Joels M. Glucocorticoids alter calcium conductance and calcium channel subunit expression in basolateral amygdala neurons. Eur J Pharmacol 16 (2002) 1083-1089
25. Kato T., Otsu Y., Furune Y., and Yamamoto T. Different effects of L-, N- and T-type calcium channel blockers on striatal dopamine release measured by microdialysis in freely moving rats. Neurochem Int 21 (1992) 99-107
26. 2+ for drug development: chronic nicotine treatment upregulates L-type high voltage-gated calcium channels. J Pharmacol Sci 97 (2005) 344-347
27. Kliethermes C.L., Finn D.A., and Crabbe J.C. Validation of a modified mirrored chamber sensitive to anxiolytics and anxiogenics in mice. Psychopharmacology 169 (2003) 190-197
28. Kuzmin A., Zvartau E., Gessa G.L., Martellotta M.C., and Fratta W. Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice. Pharmacol Biochem Behav 41 (1992) 491-500
29. Lapin I.P. Anxiogenic effect of phenylethylamine and amphetamine in the elevated plus-maze in mice and its attenuation by ethanol. Pharmacol Biochem Behav 44 (1993) 241-243
30. Lin H.Q., Burden P.M., Christie M.J., and Johnston G.A.R. The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharmacol Biochem Behav 62 (1999) 403-408
31. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92 (1987) 180-185
32. Little H.J. The role of calcium channels in drug dependence. Drug Alcohol Depend 38 (1995) 173-194
33. Malin D.H. Nicotine dependence. Studies with a laboratory model. Pharmacol Biochem Behav 70 (2001) 551-559
34. NSDUH. Results from the 2002 National Survey on Drug Use and Health, Substance Abuse and Mental Health Services Administration Office of Applied Studies (2002), Rockville, MD 13
35. Ouagazzal A.M., Kenny P.J., and File S.E. Modulation of behaviour on trials 1 and 2 in the elevated plus-maze test of anxiety after systemic and hippocampal administration of nicotine. Psychopharmacology 144 (1999) 54-60
36. Pani L., Kuzmin A., Diana M., De Montis G., Gessa G.L., and Rossetti Z.L. Calcium channel antagonists modify cocaine effects in the central nervous system differently. Eur J Pharmacol 190 (1990) 217-221
37. Pellow S., Chopin P., File S.E., and Briley M. Validation of open:closed arm entries in an elevated plus maze as a measure of anxiety in the rats. J Neurosci Methods 14 (1985) 149-167
38. Pezze M.A., and Feldon J. Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol 74 (2004) 301-320
39. Pierce R.C., and Kalivas P.W. A circuitry model of the expression to amphetamine-like psychostimulants. Brain Res Rev 25 (1997) 192-216
40. Pierce R.C., Quich E.A., Reeder D.C., Morgan Z.R., and Kalivas R.W. Calcium-mediated second messengers modulate the expression of behavioral sensitization to cocaine. J Pharmacol Exp Ther 286 (1998) 1171-1176
41. Prince R.J., Fernandes K.G., Gregory J.C., Martyn I.D., and Lippiello P.M. Modulation of nicotine-evoked [3H]dopamine release from rat striatal synaptosomes by voltage-sensitive calcium channel ligands. Biochem Pharmacol 52 (1996) 613-618
42. Pomerleau O.F. Nicotine as a psychoactive drug: anxiety and pain reduction. Psychopharmacol Bull 22 (1986) 865-869
43. 2+ channels mediate adaptation of extracellular signal-regulated kinase 1/2 phosphorylation in the ventral tegmental area after chronic amphetamine treatment. J Neurosci 24 (2004) 7464-7476
44. Reimer A.R., and Martin-Iverson M.T. Nimodipine and haloperidol attenuate behavioural sensitization to cocaine but only nimodipine blocks the establishment of conditioned locomotion induced by cocaine. Psychopharmacology 113 (1994) 404-410
45. Roll J.M., Higgins S.T., Budney A.J., Bickel W.K., and Badger G.J. A comparison of cocaine-dependent cigarette smokers and non-smokers on demographic drug use and other characteristics. Drug Alcohol Depend 40 (1996) 195-201
46. Salas R., Pieri F., Fung B., Dani J.A., and De Biasi M. Altered anxiety-related responses in mutant mice lacking the β4 subunit of the nicotinic receptor. J Neurosci 23 (2003) 6255-6263
47. Schechter M.D., and Meehan S.M. Further evidence for the mechanisms that may mediate nicotine discrimination. Pharmacol Biochem Behav 41 (1992) 807-812
48. Schoffelmeer A.N.M., De Vries T.J., Wardeh G., van de Ven H.W.M., and Vanderschuren L.J.M.J. Psychostimulant-induced behavioral sensitization depends on nicotinic receptor activation. J Neurosci 22 (2002) 3269-3276
49. Shinnick-Gallagher P., McKernan M.G., Xie J., and Zinebi F. L-type voltage-gated calcium channels are involved in the in vivo and in vitro expression of fear conditioning. Ann NY Acad Sci 985 (2003) 135-149
50. Williamson S., Gossop M., Powls B., Griffith P., Fountain J., and Strang J. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 44 (1997) 87-94
51. Wise R.A., and Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol Rev 94 (1987) 469-492
52. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 20 (1997) 92-98